Published On: Mon, Apr 20th, 2015

Teva to pay $512 million in Provigil settlement – report

"Reuters" said the settlement would be the largest ever paid over allegations of delaying generic drugs.

Teva CEO Erez Vigodman

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has agreed to pay $512 million to settle a class action suit, reports “Reuters.” The class action claims that Cephalon Inc., which Teva bought in 2011, “used anticompetitive settlements to delay generic versions of its wakefulness drug Provigil, according to court papers, ” says “Reuters.”
GLOBES logo-eng (1)
Read more about: , , ,

Wordpress site Developed by Fixing WordPress Problems